Arch Therapeutics Inc (Arch Therapeutics), operates as a medical device company. The company develops self-assembling barrier technologies to improve interventional wound care outcomes. The company offers hemostasis and sealant products to seal and protect leaking and bleeding tissue. It provides interventional wound care products. Arch Therapeutics’ products are used for adhesion prevention, gastrointestinal anastomosis, burns, diabetic ulcers, pressure ulcers, ocular applications, and others. The company also develops products such as AC5 advanced wound system and AC5 topical hemostat1, a self-assembling peptide (SAP) comprising naturally occurring amino acids. It serves its operation across the US. Arch Therapeutics is headquartered in Framingham, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Arch Therapeutics Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Arch Therapeutics Inc Company Overview
Arch Therapeutics Inc Company Snapshot
Arch Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
Apr 05, 2023: Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5 Advanced Wound System now in effect
Mar 09, 2023: Arch Therapeutics’ AC5 advanced wound system receives dedicated HCPCS billing code from The Centers for Medicare & Medicaid Services
Mar 07, 2023: Arch Therapeutics announces addition of contract sales force to advance commercialization of AC5 advanced wound system in government facilities
Jan 18, 2023: Arch Therapeutics announces formation of Medical Advisory Board to advance commercialization of AC5 Advanced Wound System
Oct 18, 2022: Key opinion leaders presented Arch Therapeutics AC5 advanced wound system at 2022 Symposium on Advanced Wound Care (SAWC) Fall
Oct 11, 2022: Arch Therapeutics’ AC5 advanced wound system to be presented with honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
Sep 23, 2022: Arch Therapeutics announces first shipments of AC5 advanced wound system under new reimbursement support program